Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $3.03 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Advaxis’ earnings, with the highest sales estimate coming in at $3.05 million and the lowest estimate coming in at $3.00 million. Advaxis posted sales of $3.79 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 20.1%. The company is expected to report its next quarterly earnings results on Friday, March 9th.

On average, analysts expect that Advaxis will report full year sales of $3.03 million for the current year, with estimates ranging from $12.21 million to $13.00 million. For the next financial year, analysts anticipate that the company will report sales of $12.68 million per share, with estimates ranging from $12.27 million to $13.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Advaxis.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $3.05 million.

Several brokerages have recently weighed in on ADXS. ValuEngine downgraded Advaxis from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 3rd. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Advaxis in a report on Wednesday, November 8th. Finally, Cantor Fitzgerald set a $19.00 price objective on Advaxis and gave the stock a “buy” rating in a report on Friday, December 22nd.

In related news, CFO Sara Bonstein sold 12,734 shares of Advaxis stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the sale, the chief financial officer now directly owns 244,504 shares in the company, valued at approximately $779,967.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Robert Petit sold 12,625 shares of Advaxis stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the sale, the insider now owns 237,265 shares of the company’s stock, valued at $756,875.35. The disclosure for this sale can be found here. Insiders sold a total of 38,192 shares of company stock valued at $122,615 over the last quarter. 7.21% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADXS. Bank of Montreal Can increased its holdings in Advaxis by 16,465.9% in the 4th quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock worth $1,230,000 after buying an additional 430,583 shares in the last quarter. Nexthera Capital LP increased its holdings in Advaxis by 160.3% in the 2nd quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock worth $1,635,000 after buying an additional 155,200 shares in the last quarter. Vanguard Group Inc. increased its holdings in Advaxis by 7.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock worth $11,572,000 after buying an additional 119,980 shares in the last quarter. OxFORD Asset Management LLP bought a new stake in Advaxis in the 2nd quarter worth about $498,000. Finally, DAFNA Capital Management LLC increased its holdings in Advaxis by 43.6% in the 2nd quarter. DAFNA Capital Management LLC now owns 247,000 shares of the biotechnology company’s stock worth $1,603,000 after buying an additional 75,000 shares in the last quarter. Institutional investors own 42.89% of the company’s stock.

Shares of Advaxis (NASDAQ:ADXS) traded down $0.23 during trading hours on Thursday, hitting $2.95. The stock had a trading volume of 1,274,373 shares, compared to its average volume of 1,020,000. Advaxis has a 1 year low of $2.71 and a 1 year high of $10.06. The company has a market capitalization of $121.14, a P/E ratio of -1.28 and a beta of 1.91.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://theolympiareport.com/2018/01/28/zacks-brokerages-expect-advaxis-inc-adxs-will-announce-quarterly-sales-of-3-03-million.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.